At the IGTP TODAY
The funds raised in the 2022 edition of La Marató de 3Cat will enable 71 research teams to conduct 37 projects in cardiovascular health to advance in the prevention, diagnosis, and treatment of diseases that represent the leading cause of death in developed countries. One of the awarded projects involves the participation of researchers from the GCAT of the IGTP, and is coordinated by Dr Camille Lassale from ISGlobal.
A collaborative study led by researchers from IGTP has revealed the promising possibilities of using an agarose spot migration assay to examine the ability of extracellular vesicles to attract other cells in a controlled environment. The study has been recently published in the journal BMC Biology.
The research, led by Cima Universidad de Navarra, sheds light on new possibilities for addressing various types of cancer. This work has been carried out in collaboration with Dr Carolina Armengol, leader of IGTP’s Childhood Liver Oncology (C-LOG) group, a pioneer in the study of childhood liver cancer in Spain.
The first urine test that detects kidney fibrosis as an alternative to kidney biopsies, an initiative from the IVECAT group, and a project applying artificial intelligence to rapidly categorise stroke patients and enhance their recovery chances, from the Neurovascular Research group, are two of the fifteen projects from Catalan research centres selected within the 2023 call of the new CaixaImpulse Healthcare Innovation programme.
An article published in Nature Communications on the pilot study carried out in Catalonia to evaluate the self-collection of biological samples reveals the high acceptability of the proposal and the key role of diagnosis in people without symptoms of mpox.
A study has identified a molecule that could potentially be a target for the development of immunotherapies, led by IrsiCaixa AIDS Research Institute and spearheaded by Julia García-Prado, principal investigator at the same centre and scientific director of the Germans Trias i Pujol Research Institute (IGTP).
The collaborative project InMaM, part of the Complementary Plan for Biotechnology Applied to Health, involving both Catalonia and the Basque Country, aims to discover new immunotherapy-based treatments for metastatic breast cancer.
A study co-led by researchers from IGTP, IIB Sant Pau and IDIBGI concludes that direct transport to a referral centre for endovascular treatment may not be the best option for patients with a final diagnosis of intracerebral haemorrhage or haemorrhagic stroke.
A study published in Nature unveils new genetic insights into COVID-19 susceptibility and severity. This work marks a significant advancement in our understanding of the role genetics play in determining COVID-19 outcomes.
The Ibero-American network RIGHT PLUS, of which the CEEISCAT is a founding member and, together with Coalition Plus, co-coordinator, has presented its launch at a meeting in Buenos Aires (Argentina) on 28-29 August.
